Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNMBiotechnology
-$0.39 today
- Market cap
- $326.66M
- Beta
- 0.89
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$1.57
Volume 0.20M
Average 0.26M
Returns on capital
Contineum Therapeutics, Inc. Class A Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-23.0%
avg -37.3%
ROIC
-25.3%
avg -30.4%
ROA
-21.7%
avg -22.6%
Analysis
ROA is currently the strongest return metric at -21.7% versus its period average of -22.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Carmine N. Stengone | President, Chief Executive Officer & Director | USD 1.12M | 50 | 17.22K | 0.05% |
Timothy R. Watkins | Chief Medical Officer & Head of Development | USD 778.77K | 52 | — | — |
Peter T. Slover | Chief Financial Officer | USD 737.64K | 51 | 192.00K | 0.51% |
John Healy | General Counsel & Corporate Secretary | USD 612.78K | 54 | — | — |
Daniel S. Lorrain | Chief Science Officer | USD 565.02K | 57 | 33.26K | 0.09% |
Steve E. Kunszabo | Senior Director of Investor Relations & Corporate Communications | — | — | — | — |
Julie S. Iwashita | Senior Vice President of Clinical Operations | — | — | — | — |
Kristina Haeckl Rac | Senior Vice President of Regulatory Affairs | — | — | — | — |
Austin Chen | Senior Vice President & Head of Research | — | — | — | — |
Morgan Paulsen | Senior Manager of Accounting | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 8, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
30
$1.84M
Net Transaction Value
−$1.84M
Net selling
Most Active
Lorrain Daniel S.
18 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 8, 26Sep 8, 2026 | Stengone Carmine N. Direct | Sell | $41.1K$41,141.50 |
| Aug 3, 26Aug 3, 2026 | Stengone Carmine N. Direct | Sell | $40K$40,029.00 |
| Jul 9, 26Jul 9, 2026 | Lorrain Daniel S. Direct | Sell | $400$400.00 |
| Jul 8, 26Jul 8, 2026 | Stengone Carmine N. Direct | Sell | $40K$40,000.00 |
| Jul 1, 26Jul 1, 2026 | Lorrain Daniel S. Direct | Sell | $91.7K$91,681.53 |
| Jul 1, 26Jul 1, 2026 | Lorrain Daniel S. Direct | Sell | $40.6K$40,608.49 |
| Jun 30, 26Jun 30, 2026 | Lorrain Daniel S. Direct | Sell | $462.3K$462,288.33 |
| Jun 30, 26Jun 30, 2026 | Watkins Tim Direct | Sell | $173.6K$173,590.16 |
| Jun 30, 26Jun 30, 2026 | Stengone Carmine N. Direct | Sell | $160.1K$160,080.00 |
| Jun 1, 26Jun 1, 2026 | Lorrain Daniel S. Direct | Sell | $54.9K$54,862.19 |
1–10 of 30
Summary
Insiders reported 0 buys worth $0.00 and 30 sells worth $1.84M over the last 12 months. That adds up to net selling of $1.84M. Lorrain Daniel S. was the most active insider with 18 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Contineum Therapeutics, Inc. Class A Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about CTNM's management, answered from reported figures.
Who manages CTNM?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) lists 10 active executives. The top listed executive is Timothy R. Watkins, Chief Medical Officer & Head of Development.
Are CTNM insiders buying or selling?
Recent insider activity shows net buying of $39.61M.
Continue the stock analysis
Jump to another research area for this company.